10 Top Performing European Stocks Heading into 2025

2) Oculis Holding AG (NASDAQ:OCS)

% Increase on a YTD Basis: ~47.33%

Average Upside Potential: ~78.1%

Oculis Holding AG (NASDAQ:OCS) is a clinical-stage biopharmaceutical company, which is engaged in developing drug candidates to treat ophthalmic diseases. The company is based in Zug, Switzerland.

Oculis Holding AG (NASDAQ:OCS) remains focused on the development of innovative treatments to improve eye care and save sight. This is expected to be aided by a differentiated pipeline of product candidates that are targeted at addressing unmet medical needs in ophthalmology. Wall Street analysts believe that Oculis Holding AG (NASDAQ:OCS) has strengthened its leadership team given the recent appointments of Sharon Klier, M.D. as Chief Development Officer and Daniel S. Char as Chief Legal Officer.

These developments, together with a robust balance sheet, place the company well to drive execution in pipeline development and create value for key stakeholders. As of September 30, 2024, Oculis Holding AG (NASDAQ:OCS) had total cash, cash equivalents, and short-term investments of CHF 105.5 million ($125.0 million) and these balances should finance its operations into H2 2026. Moving forward, the company continues to prepare itself for a New Drug Application (NDA) submission for OCS-01 in early 2025.

Oculis Holding AG (NASDAQ:OCS) is optimistic about ramping up the late-stage pipeline and transitioning to the commercial phase. This optimism stems from an experienced leadership team and strategic planning targeted at improving patient outcomes in the ophthalmology sector. It plans to consult with the FDA in Q1 2025 to discuss the positive topline results from the Phase 2b RELIEF trial, together with the next steps for OCS-02 (licaminlimab) development.

As per Wall Street analysts, the shares of Oculis Holding AG (NASDAQ:OCS) have an average price target of $29.67.